Povetacicept reduces disease activity in MG mouse model
Povetacicept reduced disease activity in a mouse model of MG by reducing the levels of disease-causing antibodies in the bloodstream.| Myasthenia Gravis News
Povetacicept reduced disease activity in a mouse model of MG by reducing the levels of disease-causing antibodies in the bloodstream.| Myasthenia Gravis News
Myasthenia gravis occurs when self-reactive antibodies mistakenly attack the body's immune system, causing muscle weakness and fatigue.| Myasthenia Gravis News
Mestinon (pyridostigmine bromide) is an oral therapy approved for the treatment of myasthenia gravis (MG).| Myasthenia Gravis News
People with gMG with difficulty getting diagnosed or hard-to-manage disease symptoms accrue higher healthcare-related costs, per a study.| Myasthenia Gravis News
Scientists have identified a set of inflammatory molecules that could be useful as biomarkers to aid in MG diagnosis and classification.| Myasthenia Gravis News
Myasthenia gravis is a neuromuscular disease characterized by weakness and fatigue that can affect muscles involved in voluntary movements.| Myasthenia Gravis News
